The study objectives were to assess the clinical efficacy, immune function (including CD3+, CD4+, CD8+, CD4+/CD8+, natural killer (NK) cell count, IgA, IgG, and IgM), adverse events such as nausea and vomiting, thrombocytopenia, and leukopenia of combination therapy in patients with advanced NSCLC (Figure 1). This evidence concerns the gene CD8A and Decreased total leukocyte count.